TCM
RCUS icon

Tekla Capital Management’s Arcus Biosciences RCUS Stock Holding History

Tekla Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$667K Hold
32,839
– – 0.03% 135
2023
Q1 		$599K Buy
+32,839
New +$628K 0.02% 143

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Tekla Capital Management's RCUS Position: Q2 2023 in Review

Tekla Capital Management held its Arcus Biosciences (RCUS) position steady in Q2 2023 at 32,839 shares worth $667K. The position accounts for 0.03% of the portfolio, ranked #135.

Tekla Capital Management first reported a position in RCUS in Q1 2023 and has held it in 2 quarters since. 181 funds tracked by Wall St. Rank hold RCUS as of Q2 2023.

  • Tekla Capital Management held 32,839 shares of Arcus Biosciences worth $667K as of Q2 2023.
  • Tekla Capital Management left its Arcus Biosciences share count unchanged in Q2 2023.
  • Arcus Biosciences made up 0.03% of Tekla Capital Management's portfolio in Q2 2023, its #135 holding.
  • Tekla Capital Management first reported a position in Arcus Biosciences in Q1 2023 and has held it in 2 quarters since.
  • 181 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.